VEGF is a mediator in the pathogenesis of certain eye conditions, including wet age-related macular degeneration (AMD), diabetic retinopathy and macular oedema secondary to retinal vein occlusions.

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular ...

Diabetic macular edema develops when fluid accumulates in the macula, the retina’s center responsible for sharp, detailed vision. This swelling distorts sight, compromising daily activities like ...

Background: Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduces the risk of visual loss. However recurrences are common and despite laser treatment ...

Therefore, it would not be an efficient use of NHS resources to conduct an evaluation. Aflibercept 8mg should therefore be considered for routine commissioning.

MSD (Merck & Co) and its wholly-owned subsidiary EyeBio have announced the start of the Phase IIb/III BRUNELLO clinical trial ...

cataract operation) or Yag procedure with the risk of further aggravating the macular oedema, intra-ocular pressure > 25 mmHg or any established glaucoma patient, ocular or systemic infection ...

Afqlir is indicated not only for nAMD but also for macular oedema following retinal vein occlusion, myopic choroidal neovascularisation and diabetic macular oedema. Sandoz chief scientific officer ...

Bayer HealthCare's Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular oedema (DMO).

age related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion, visual impairment due to diabetic macular oedema, and visual impairment due to ...